Zentalis Pharmaceuticals, Inc. (ZNTL)
NASDAQ: ZNTL · Real-Time Price · USD
3.000
+0.070 (2.39%)
Dec 20, 2024, 4:00 PM EST - Market closed
Zentalis Pharmaceuticals Stock Forecast
Stock Price Forecast
The 8 analysts with 12-month price forecasts for ZNTL stock have an average target of 10.5, with a low estimate of 4.00 and a high estimate of 20. The average target predicts an increase of 250.00% from the current stock price of 3.00.
Analyst Consensus: Buy
* Price targets were last updated on Nov 15, 2024.
Analyst Ratings
The average analyst rating for ZNTL stock from 8 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 3 | 3 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 4 | 4 | 4 | 4 | 4 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Guggenheim | Guggenheim | Strong Buy Maintains $12 → $8 | Strong Buy | Maintains | $12 → $8 | +166.67% | Nov 15, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +566.67% | Nov 15, 2024 |
| Oppenheimer | Oppenheimer | Buy Reiterates $20 | Buy | Reiterates | $20 | +566.67% | Sep 16, 2024 |
| Wedbush | Wedbush | Sell → Hold Upgrades $4 | Sell → Hold | Upgrades | $4 | +33.33% | Aug 12, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +566.67% | Aug 12, 2024 |
Financial Forecast
Revenue This Year
36.89M
Revenue Next Year
n/a
from 36.89M
EPS This Year
-2.50
from -4.47
EPS Next Year
-2.99
from -2.50
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 43.1M | n/a | 177.6M | |||
| Avg | 36.9M | n/a | 27.5M | |||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -2.43 | -2.60 | -1.07 | |||
| Avg | -2.50 | -2.99 | -2.89 | |||
| Low | -2.63 | -3.40 | -3.66 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.